/
NOVT
$157.75+$0.19 (+0.12%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$5.6B
36M shares
52-week range
$98.27 – $171.85
81% from low
Sector
MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$22.99
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $614.3M | $626.1M | $590.6M | $706.8M | $860.9M | $881.7M | $949.2M | $980.6M |
| Cost of revenue | $352.8M | $364.0M | $346.1M | $406.5M | $482.4M | $481.8M | $527.7M | $572.8M |
| Gross profit | $261.5M | $262.1M | $244.5M | $300.3M | $378.5M | $399.9M | $421.5M | $407.8M |
| Gross margin | 42.6% | 41.9% | 41.4% | 42.5% | 44.0% | 45.4% | 44.4% | 41.6% |
| R&D | $51.0M | $56.0M | $61.0M | $72.5M | $85.8M | $91.7M | $95.5M | $95.5M |
| Operating income | $71.0M | $55.3M | $55.9M | $64.1M | $103.1M | $110.5M | $110.6M | $116.7M |
| EBITDA | $116.1M | $110.1M | $98.0M | $125.5M | $160.6M | $169.9M | $179.9M | $153.0M |
| Net income | $49.1M | $40.8M | $44.5M | $50.3M | $74.1M | $72.9M | $64.1M | $53.8M |
| Net margin | 8.0% | 6.5% | 7.5% | 7.1% | 8.6% | 8.3% | 6.8% | 5.5% |
| EPS (diluted) | 1.43 | 1.15 | 1.25 | 1.41 | 2.06 | 2.02 | 1.77 | 1.47 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.1B | $3.59 | $3.55–$3.62 | 2 |
| 2027 | $1.1B | $4.14 | $4.11–$4.16 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$44.73
Price
$157.75
Implied downside
-72%
Peer comparison
Novanta Inc. Common Stock
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
www.novanta.com- Employees
- 3,000
- IPO / List date
- Mar 24, 1999
- HQ
- BEDFORD, MA
Held by traders on TradeandTell
No one on the platform currently holds NOVT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 95,600 | $9.6M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NOVT yet.
